HNSALV Trial: Combining Immunotherapy With Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck Cancers
Latest Information Update: 23 May 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Feb 2022 to 1 May 2022.
- 01 Mar 2022 Status changed from not yet recruiting to recruiting.
- 16 Dec 2021 Planned initiation date changed from 1 Mar 2021 to 1 Feb 2022.